图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫学评论综述™
影响因子: 1.352 5年影响因子: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 打印: 1040-8401
ISSN 在线: 2162-6472

免疫学评论综述™

DOI: 10.1615/CritRevImmunol.v29.i5.30
pages 399-418

Current Vaccination Strategies for the Treatment of B-Cell Lymphoma and Multiple Myeloma

Nurit Hollander
Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

ABSTRACT

Therapeutic vaccines have been developed to induce immune responses capable of eradicating lymphoma and myeloma tumors. Most of these vaccines target the immunoglobulin idiotype (Id) as a tumor-specific antigen. Phase I/II clinical trials of Id vaccination in lymphoma demonstrated that some lymphoma patients could mount immune responses that were correlated with a favorable clinical outcome. These encouraging results initiated phase III trials of Id vaccination in lymphoma, the results of which have been recently released. Disappointingly, only one of three phase III studies achieved the primary end point of progression-free survival. Detailed analysis of these results is awaited to help identify factors that determine clinical efficacy of Id vaccination as reflected in the three trials. Unlike lymphoma, studies of Id vaccination in multiple myeloma have yielded far less evidence of clinical benefit. Although Id vaccines induce immune responses in myeloma patients, their efficacy is insufficient to provide a clear clinical benefit. Strategies to improve lymphoma and myeloma vaccines are currently tested with an emphasis on optimization of antigen delivery and presentation and modulation of the immune system toward enhancement of T-cell function. Despite many hurdles yet to overcome, it is hoped that newly developed strategies that augment both immune and clinical responses will allow effective vaccination resulting in tumor eradication.


Articles with similar content:

Role of Toll-Like Receptors in Hepatitis C Virus Pathogenesis and Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 4
Saba Khaliq, Usman Ali Ashfaq, Muhammad Sarfaraz Iqbal
The Immune System in the Pathogenesis of Ovarian Cancer
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, Melissa S. DeRycke, Bridget Charbonneau
Immunotherapeutic Approaches to Head and Neck Cancer
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Hassan Nasser, Maie St. John
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Hasan Badar, Muhammad Muzammil, Sundas Jehanzeb, Deepika Sarvepalli, Muhammad Talha Khan, Asad ur Rahman, Waqas Ullah
Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Tahir Farooq, Muhammad Ibrahim, Tahsin Gulzar, Matloob Ahmed, Muhammad Sajid Hamid Akash, Arruje Hameed, Kanwal Rehman